Myriad Genetics Inc Market Cap ($321.38 Million)
Market Cap & Net Worth: Myriad Genetics Inc (MYGN)
Myriad Genetics Inc market cap. Myriad Genetics Inc (NASDAQ:MYGN) has a market capitalization of $321.38 Million ($321.38 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14179 globally and #3407 in its home market, demonstrating a 0.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Myriad Genetics Inc's stock price $6.04 by its total outstanding shares 95649645 (95.65 Million). Also see MYGN operating cash flow for how efficiently the company converts equity into cash flow.
Myriad Genetics Inc Market Cap History (2015–2026)
Myriad Genetics Inc market cap history from 2015 to 2026. Data shows change from $4.13 Billion to $577.72 Million (-15.74% CAGR). Check MYGN share price today for real-time trading data and today's change.
Index Memberships
Myriad Genetics Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.14 Trillion | 0.03% | #26 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #377 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1386 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.06% | #561 of 602 |
Weight: Myriad Genetics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Myriad Genetics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Myriad Genetics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Myriad Genetics Inc (MYGN) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.71x
Myriad Genetics Inc's market cap is 0.71 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.59 Billion | $740.50 Million | $117.20 Million | 2.15x | 13.60x |
| 2017 | $3.29 Billion | $728.70 Million | $17.40 Million | 4.51x | 188.80x |
| 2018 | $2.78 Billion | $743.70 Million | $133.30 Million | 3.74x | 20.86x |
| 2019 | $2.60 Billion | $851.10 Million | $4.60 Million | 3.06x | 566.20x |
| 2020 | $1.89 Billion | $557.00 Million | -$223.70 Million | 3.40x | N/A |
| 2021 | $2.64 Billion | $690.60 Million | -$27.20 Million | 3.82x | N/A |
| 2022 | $1.39 Billion | $678.40 Million | -$112.00 Million | 2.05x | N/A |
| 2023 | $1.83 Billion | $753.20 Million | -$263.30 Million | 2.43x | N/A |
| 2024 | $1.31 Billion | $837.60 Million | -$127.30 Million | 1.57x | N/A |
| 2025 | $588.25 Million | $824.50 Million | -$365.90 Million | 0.71x | N/A |
Competitor Companies of MYGN by Market Capitalization
Companies near Myriad Genetics Inc in the global market cap rankings as of November 5, 2026. Also see Myriad Genetics Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Myriad Genetics Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #142 globally with a market cap of $162.54 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #479 globally with a market cap of $56.02 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #546 globally with a market cap of $48.96 Billion USD ( CN¥334.59 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $698.34 |
| #142 | Danaher Corporation | NYSE:DHR | $162.54 Billion | $230.11 |
| #479 | Natera Inc | NASDAQ:NTRA | $56.02 Billion | $388.63 |
| #546 | WuXi AppTec Co Ltd | SHG:603259 | $48.96 Billion | CN¥135.28 |
Market Capitalization of Myriad Genetics Inc (2015–2026)
Market capitalization of Myriad Genetics Inc from 2015 to today. Between 2015 and today, Myriad Genetics Inc's market cap moved from $4.13 Billion to $ 577.72 Million, with a yearly change of -15.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $577.72 Million | -1.79% |
| 2025 | $588.25 Million | -55.14% |
| 2024 | $1.31 Billion | -28.37% |
| 2023 | $1.83 Billion | +31.91% |
| 2022 | $1.39 Billion | -47.43% |
| 2021 | $2.64 Billion | +39.57% |
| 2020 | $1.89 Billion | -27.38% |
| 2019 | $2.60 Billion | -6.33% |
| 2018 | $2.78 Billion | -15.36% |
| 2017 | $3.29 Billion | +106.03% |
| 2016 | $1.59 Billion | -61.38% |
| 2015 | $4.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Myriad Genetics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $321.38 Million USD |
| MoneyControl | $321.38 Million USD |
| MarketWatch | $321.38 Million USD |
| marketcap.company | $321.38 Million USD |
| Reuters | $321.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more